In the present study, we demonstrated that 15d-PGJ2 was able to reduce the RA-induced TMJ inflammatory hypernociception by an indirect mechanism. This antinociceptive effect is in part due to decrease of TNF-α, IL-1β and KC levels and PKA/PKCε expression in the TMJ.
The aim of this study was to evaluate the peripheral effect of 15d-PGJ2 in Rheumatoid Arthritis-induced inflammation in the temporomandibular joint (TMJ) of rats. Antigen-induced arthritis (AIA) was generated in rats with methylated bovine serum albumin (mBSA) diluted in complete Freund's adjuvant. Pretreatment with an intra-articular injection of 15d-PGJ2 (100 ng/TMJ) before mBSA intra-articular injection (10 µg/TMJ) (challenge) in immunized rats significantly reduced the RA-induced hypernociception (p<0.05; ANOVA, Tukey test). Corroborating these results, 15d-PGJ2 was able to inhibit plasma extravasation, leukocyte migration and the release of inflammatory cytokines TNF-α, IL-1β, IL-6, IL-12, IL-18 and the chemokine KC and CINC-1 (p<0,05: ANOVA, Tukey Test). Moreover, the effect of 15d-PGJ2 to increase the decay accelerating factor (CD55) expression associated to decrease pro-inflammatory cytokines release may explain the inhibition of leukocyte infiltration, through a shift in the balance of the pro- and anti-adhesive properties. To confirm these results histopathological analysis showed that 15d-PGJ2 reduced the inflammatory parameters induced by RA. Thus, 15d-PGJ2 might be used as a potential anti-inflammatory drug to treat RA inflammation of the temporomandibular joint.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.